減毒活疫苗市場：依產品類型、技術、適應症、給藥方式、年齡層、分銷管道和地區

2025年全球減毒活疫苗市場規模估計為 295億美元，預計到2032年將達到 632.1億美元，2025-2032年年複合成長率為 11.5%。

圖表.減毒活疫苗市場佔有率（%），依地區分類（2025年）

減毒活疫苗使用減毒或死亡的活微生物或病原體來誘導免疫。當這些疫苗給患者注射時，它們會模擬自然感染，但不會引起疾病。常見的減毒活疫苗包括麻疹、腮腺炎、德國德國麻疹（MMR）、水痘、輪狀病毒和黃熱病疫苗。預計在預測期內，全球預防性醫療保健意識的提高和疫苗接種計劃的增加將推動該市場的成長。

市場動態：

預計新興國家政府對疫苗接種計劃的投資增加將在預測期內推動市場成長。此外，麻疹、流行性腮腺炎和德國德國麻疹等各種疾病發生率的上升也進一步推動了對減毒活疫苗的需求。然而，疫苗開發高成本、核准規定嚴格是限制市場成長的主要因素。另一方面，針對新興疾病的疫苗研發工作進行中，新型減毒疫苗的核准可能為市場參與企業帶來具有吸引力的成長機會。

本研究的主要特點

本報告對全球減毒活疫苗市場進行了詳細分析，以2024年為基準年，並提供了預測期（2025-2032年）的市場規模（十億美元）和年複合成長率（CAGR%）。

強調了各個領域的潛在商機，並解釋了該市場的有吸引力的投資提案矩陣。

提供有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。

本報告根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球減毒活疫苗市場的主要企業。

主要企業包括GlaxoSmithKline plc、Merck & Co.、Pfizer, Inc.、Astellas Pharma Inc.、Johnson & Johnson、CSL Limited、Emergent BioSolutions、MedImmune, LLC、Sanofi、Serum Institute of India Pvt.Ltd.、Bharat Biotech、Takeda Pharmaceutical Company、Novartis AG、BioNTech SE、Sinovac Biotech Ltd.。

本報告提供的見解將幫助負責人和企業經營團隊未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。

本研究報告針對該產業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。

相關人員可以透過用於分析全球減毒活疫苗市場的各種策略矩陣來促進他們的決策。

目錄

第1章 研究目的與前提

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要

第3章 市場動態、法規與趨勢分析

• 市場動態
• 促進因素
• 限制因素
• 機會
• 影響分析
• 主要進展
• 監管情景
• 產品發布/核准
• PEST分析
• 波特分析
• 併購場景
• 產業趨勢

第4章 2025-2032年全球減毒活疫苗市場（依產品類型）

• 細菌
• 病毒

第5章 2025-2032年全球減毒活疫苗市場（依技術）

• 傳統技術
• 減毒活體技術
• 去活化/滅菌
• 進階技術
• 重組DNA技術
• 病毒載體技術

第6章 2025-2032年全球減毒活疫苗市場（依適應症）

• 結核
• 麻疹
• 輪狀病毒
• 黃熱病
• 口服脊髓灰質炎
• 其他

第7章 2025-2032年全球減毒活疫苗市場（依給藥方式）

• 注射
• 鼻內
• 口服
• 其他

第8章 2025-2032年全球減毒活疫苗市場（依年齡層）

• 兒童疫苗
• 成人疫苗
• 老年人疫苗

第9章 2025-2032年全球減毒活疫苗市場（依通路）

• 醫院藥房
• 零售藥局
• 網路藥局

第10章 2020-2032年全球減毒活疫苗市場（依地區）

• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第11章 競爭格局

• GlaxoSmithKline plc
• Merck & Co.
• Pfizer, Inc.
• Astellas Pharma Inc.
• Johnson & Johnson
• CSL Limited
• Emergent BioSolutions, Inc.
• MedImmune, LLC
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Bharat Biotech
• Takeda Pharmaceutical Company
• Novartis AG
• BioNTech SE
• Sinovac Biotech Ltd.

第12章 分析師建議

• 命運之輪
• 分析師觀點
• Coherent Opportunity Map

第13章 參考文獻與調查方法

• 參考
• 調查方法
• 關於出版商

Global Life Attenuated Vaccines Market is estimated to be valued at US$ 29.50 Bn in 2025 and is expected to reach US$ 63.21 Bn by 2032, growing at a compound annual growth rate (CAGR) of 11.5% from 2025 to 2032.

Figure. Life Attenuated Vaccines Market Share (%), By Region 2025

Life attenuated vaccines use weakened or attenuated live microorganisms or pathogens to trigger immunity. When administered to a patient, these vaccines mimic a natural infection but do not cause the disease. Common life attenuated vaccines include measles, mumps, rubella (MMR), varicella, rotavirus, and yellow fever vaccines. Growing awareness regarding preventive healthcare and rising immunization programs worldwide are expected to support the growth of this market over the forecast period.

Market Dynamics:

Increasing investments by government bodies in immunization programs across developing nations are expected to drive the market growth during the forecast period. Moreover, rising incidence of various diseases, such as measles, mumps, and rubella, is further propelling the demand for life attenuated vaccines. However, high costs associated with vaccine development and stringent regulations for approval are the major factors anticipated to restrain the market growth. On the flip side, ongoing research & development activities to develop vaccines for new diseases and approval of newer attenuated vaccines are likely to present attractive growth opportunities for the players in the market.

Key Features of the Study:

This report provides in-depth analysis of the global life attenuated vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global life attenuated vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include GlaxoSmithKline plc, Merck & Co., Pfizer, Inc., Astellas Pharma Inc., Johnson & Johnson, CSL Limited, Emergent BioSolutions, Inc., MedImmune, LLC, Sanofi, Serum Institute of India Pvt. Ltd., Bharat Biotech, Takeda Pharmaceutical Company, Novartis AG, BioNTech SE, and Sinovac Biotech Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global life attenuated vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global life attenuated vaccines market

Market Segmentation

• Product Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Bacterial
  • Viral
• Technology Insights (Revenue, USD Bn, 2020 - 2032)
  • Classical Techniques
  • Live Attenuation
  • Inactivated/Killed
  • Advanced Techniques
  • Recombinant DNA Technology
  • Viral Vector Technology
• Indication Insights (Revenue, USD Bn, 2020 - 2032)
  • Tuberculosis
  • Measles
  • Rotavirus
  • Yellow Fever
  • Oral Polio
  • Others
• Mode of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Injectable
  • Intranasal
  • Oral
  • Others
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Pediatric Vaccines
  • Adult Vaccines
  • Geriatric Vaccines
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • GlaxoSmithKline plc
  • Merck & Co.
  • Pfizer, Inc.
  • Astellas Pharma Inc.
  • Johnson & Johnson
  • CSL Limited
  • Emergent BioSolutions, Inc.
  • MedImmune, LLC
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Bharat Biotech
  • Takeda Pharmaceutical Company
  • Novartis AG
  • BioNTech SE
  • Sinovac Biotech Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Life Attenuated Vaccines Market, By Product Type
  • Global Life Attenuated Vaccines Market, By Technology
  • Global Life Attenuated Vaccines Market, By Indication
  • Global Life Attenuated Vaccines Market, By Mode of Administration
  • Global Life Attenuated Vaccines Market, By Age Group
  • Global Life Attenuated Vaccines Market, By Distribution Channel
  • Global Life Attenuated Vaccines Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Life Attenuated Vaccines Market, By Product Type, 2025-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Bacterial
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Viral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Life Attenuated Vaccines Market, By Technology, 2025-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Classical Techniques
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Live Attenuation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inactivated/Killed
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Advanced Techniques
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Recombinant DNA Technology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Viral Vector Technology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Life Attenuated Vaccines Market, By Indication, 2025-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Tuberculosis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Measles
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Rotavirus
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Yellow Fever
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oral Polio
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Life Attenuated Vaccines Market, By Mode of Administration, 2025-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Injectable
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intranasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Life Attenuated Vaccines Market, By Age Group, 2025-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pediatric Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Adult Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Geriatric Vaccines
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Life Attenuated Vaccines Market, By Distribution Channel, 2025-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Life Attenuated Vaccines Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025,2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Mode of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Mode of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Mode of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Product Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Technology, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Mode of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa

11. Competitive Landscape

• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co.
• Pfizer, Inc.
• Astellas Pharma Inc.
• Johnson & Johnson
• CSL Limited
• Emergent BioSolutions, Inc.
• MedImmune, LLC
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Bharat Biotech
• Takeda Pharmaceutical Company
• Novartis AG
• BioNTech SE
• Sinovac Biotech Ltd.

12. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

13. References and Research Methodology

• References
• Research Methodology
• About us